iShares Trust - iShares Biotechnology ETF Past Earnings Performance

Past criteria checks 1/6

There is insufficient data on iShares Trust - iShares Biotechnology ETF's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Capital Markets Industry Growth	14.7%
Revenue growth rate	-11.8%
Return on equity	5.2%
Net Margin	664.1%
Last Earnings Update	30 Sep 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How iShares Trust - iShares Biotechnology ETF makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BASE:IBBD Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses
30 Sep 23	54	359	36
30 Jun 23	56	133	36
31 Mar 23	58	-93	37
31 Dec 22	60	-1,509	37
30 Sep 22	61	-2,925	38
30 Jun 22	63	-2,121	41
31 Mar 22	65	-1,316	44
31 Dec 21	67	229	45
30 Sep 21	68	1,773	46
30 Jun 21	67	2,257	45
31 Mar 21	66	2,740	43
31 Dec 20	60	2,539	40
30 Sep 20	54	2,337	37
30 Jun 20	52	1,057	35
31 Mar 20	51	-224	33
31 Dec 19	52	-965	35
30 Sep 19	53	-1,707	36
30 Jun 19	53	-679	38
31 Mar 19	53	348	40
31 Dec 18	55	602	42
30 Sep 18	57	856	44
30 Jun 18	57	823	44
31 Mar 18	57	790	44
31 Dec 17	57	1,037	42
30 Sep 17	57	1,283	39
30 Jun 17	55	1,051	37
31 Mar 17	52	818	35
31 Dec 16	48	260	34
30 Sep 16	44	-298	34
30 Jun 16	44	-1,164	36
31 Mar 16	45	-2,030	38
31 Dec 15	38	-753	38
30 Sep 15	32	524	37
30 Jun 15	31	1,407	33
31 Mar 15	30	2,289	28
31 Dec 14	30	1,727	26
30 Sep 14	30	1,164	23
30 Jun 14	24	1,244	21
31 Mar 14	17	1,324	19

Quality Earnings: IBBD has a large one-off gain of $341.8M impacting its last 12 months of financial results to 30th September, 2023.

Growing Profit Margin: IBBD became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if IBBD's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: IBBD has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: IBBD has become profitable in the last year, making it difficult to compare its past year earnings growth to the Capital Markets industry (8%).

Return on Equity

High ROE: IBBD's Return on Equity (5.2%) is considered low.

Return on Assets

Return on Capital Employed

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/07 18:07
End of Day Share Price	2025/02/07 00:00
Earnings	2023/09/30
Annual Earnings	2023/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

iShares Trust - iShares Biotechnology ETF is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.